[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,115,0,25,[9,50,82,106,118,146,181,261,442,473,501,523,550,575,604,647,687,708,732,755,774,794,814,835,881],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053437","phase-2-stem-cell-transplantation-for-participants-with-germline-runx1-associated-blood-cancers-100053437",false,"NCT07524530","Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers","Phase II Haploidentical Hematopoietic Stem Cell Transplantation for Participants With Germline RUNX1 Associated Hematologic Malignancies","* INCLUSION CRITERIA:\n* Affected participants (Recipients)\n\n  * History of deleterious or suspected deleterious (defined as P\u002FLP or VUS with RUNX1 phenotype) germline RUNX1 mutation as defined by ClinVar (nih.gov)\n  * Histological confirmation of a myeloid malignancy - acute or chronic leukemia (\\\u003C5% marrow blasts preferred) or myelodysplastic syndrome\u002Fmyeloproliferative neoplasms (MDS\u002FMPN) (\\\u003C10% marrow blasts preferred). Participants may be treated on this study to achieve preferred blast cutoffs. Participants with poorly responsive or relapsed disease remain eligible and may proceed as the graft-versus-leukemia (GVL) effect may produce cures.\n\nSubjects requiring standard therapies to prepare for HCT should ideally be referred to this study in remission, if possible. However, sometimes disease status changes during evaluation for HCT and it is necessary to establish disease control through the administration of standard therapies during evaluation for HCT. If ongoing therapy for the underlying disease outside of the NIH is not in the best interest of the subject according to the clinical judgment of the NIH PI, then the subject may receive standard treatment for his\u002Fher underlying hematologic malignancy as a bridge to HCT on this protocol, prior to starting the research phase of the study. If it becomes apparent that the subject will not be able to proceed to HCT, then he\u002Fshe must come off study. Subjects receiving standard therapy will be told about the therapy, associated risks, potential benefits, alternatives to the proposed therapy, and the availability of receiving the same treatment elsewhere, outside of a research protocol.\n\n* Availability of a haploidentical donor (HLA-match only).\n* Age \\>= 4 and \\\u003C= 70 years\n* Karnofsky (\\>=16 years) or Lansky (\\\u003C16 years) \\>=60%\n* For human immunodeficiency virus (HIV)-infected participants, participant must be on effective anti-retroviral therapy, without uncontrolled opportunistic infection and have approval via Transplant Infectious Disease consultation. Consider donor with CCR5(delta)32 homozygosity for these participants.\n* For individuals with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load (VL) must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV VL.\n* Contraception as follows:\n\n  ---Women of child-bearing potential (WOCBP) must agree to use highly effective contraception (hormonal, intrauterine device \\[IUD\\], abstinence, surgical sterilization) at the study entry and up to and 12 months post conditioning and\u002For post-transplant.\n* Men that can father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) at the study entry and up to 12 months posttransplant or 4 months after conditioning if transplant is not done. We also will recommend men that can father children with partners that can bear children ask their partners to be on highly effective birth control (hormonal, IUD, surgical sterilization). Men that can father children must not freeze or donate sperm within the same period.\n* Breastfeeding participants must be willing to discontinue breastfeeding during the study and for 12 months post-transplant or 1 week after conditioning if transplant is not done.\n* Willingness to remain in the NIH hospital or, if discharged, stay close to the NIH (30 minutes drive), for a minimum of 100 days after transplant or longer if there are complications. The participants must commit to having an adult caregiver with them during the first 100 days after the transplant\n* Participants or parent\u002Fguardian\u002Flegally authorized representative must be able to understand and willing to sign a written informed consent document.\n* Additional criteria for recipients suitable for MAC\n\n  * Age \\\u003C= 65 years\n  * HCT-CI \\\u003C4\n  * Pulmonary function tests (PFTs): Forced expiratory volume in the first second (FEV1) and adjusted diffusion capacity of carbon monoxide (DLCO) \\>=66%, without dyspnea at rest or oxygen requirement. If too young to cooperate with PFTs, must have \\>=92% oxygen saturation on room air and no dyspnea at rest.\n  * Left ventricular ejection fraction (LVEF) \\>=50% by echocardiogram (ECHO) or Multigated Acquisition (MUGA) scan (101)\n  * Recipients must have adequate organ function as defined below:\n\n    * Total bilirubin \\\u003C1.5 x institutional upper limit of normal (iULN) (unless Gilbert disease, hemolysis)\n    * Aspartate aminotransferase (AST) \u002F Alanine aminotransferase (ALT) \\\u003C=2.5 x iULN (unless therapy related and will improve in discussion with the National Institute of Diabetes and Digestive and Kidney Diseases \\[NIDDK\\])\n    * Creatinine within normal institutional limits or 24-hour urine or calculated creatinine clearance \\>=60 mL\u002Fmin\u002F1.73 m\\^2 for individuals with creatinine levels above institutional normal (calculated using the Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] equation)\n* Additional criteria for recipients suitable for RIC\n\n  * Age \\\u003C=70 years\n  * PFTs: FEV1 and DLCO \\>=50%, without dyspnea at rest or oxygen requirement. If too young to cooperate with PFTs, must have \\>=92% oxygen saturation on room air and no dyspnea at rest\n  * LVEF \\>=40% by ECHO or MUGA obtained within 2 months of HSCT (Children s Oncology Group \\[COG\\] criteria).\n  * Recipients must have adequate organ function as defined below:\n\n    * Total bilirubin \\\u003C2.5 x iULN (unless Gilbert disease, hemolysis)\n    * AST\u002FALT \\\u003C3.5 x iULN (unless therapy related and will improve in discussion with NIDDK)\n    * Creatinine within normal institutional limits or 24-hour urine or calculated creatinine clearance \\>=50 mL\u002Fmin\u002F1.73 m\\^2 for individuals with creatinine levels above institutional normal (calculated using the CKD-EPI equation)\n* Unaffected participants\n\n  * Haploidentical donors\n\n    ----Age \\>=4 years\n  * Participants or parent\u002Fguardian must be able to understand and willing to sign a written informed consent document.\n  * Unaffected family members\n\n    * Age \\>=18 years\n    * If the participant is a blood relative of the recipient, participant must be negative for RUNX1 mutations by molecular testing\n    * Participants must be able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n-All participants\n\n* Recipients who are receiving any investigational agent except virus specific T cells (VST)\n* Active non-hematologic malignancies\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in study.\n* Participants with the following cardiac conditions: symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (except atrial fibrillation if cleared by cardiology consultation)\n* Participants without access to medical care at home.\n* Positive serum or urine beta-human chorionic gonadotropin (beta-hCG) test at screening\n* Uncontrolled intercurrent illness evaluated by history, physical exam, and laboratory studies or situations that would limit compliance with study requirements, interpretation of results or that could increase risk to the participant","ALL","4 Years","70 Years",{"count":21,"type":22},98,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Background:\n\nSome blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person is born with. Stem cell transplants are used to treat many diseases including blood cancers. Stem cell transplantation for patients with germline RUNX1 mutation driven blood cancers is standard of care and available in most major medical centers. The difference with this transplantation protocol is that it is prospective, only available to participants with germline RUNX1 variants and designed to determine the extent to which tailoring chemotherapy and supportive care medication doses for each individual patient may improve outcomes compared to data derived from retrospective transplantation protocols for patients with RUNX1 varinats which is less accurate.\n\nObjective:\n\nThe primary objective of this protocol is to determine how tailored doses of chemotherapy and supportive care medications may improve disease free survival as compared to historical\u002Fexpected disease free survival.\n\nEligibility:\n\nPeople aged 4 to 70 years with blood cancer caused by a RUNX1 gene mutation. Other participants are also needed: (1) stem cell donors; (2) relatives who do not have a mutation in the RUNX1 gene; and (3) healthy volunteers.\n\nDesign:\n\nParticipants with blood cancer will be screened during approximately 1-3 months before transplatation. They will have blood tests and tests of their heart and lung function. A sample of bone marrow may be taken.\n\nA flexible tube (central line) will be inserted into a vein in participants chest or lower neck. This line will remain in place during the hospitalization and be used to draw blood and administer drugs. These lines are almost always transitioned to a peripherally inserted central catheter (PICC) line at the time of hospital discharge.\n\nParticipants will be inpatient for 4 to 5 weeks. They will receive drugs to prepare their body for the stem cell transplant. Some may also receive radiation treatment. Other tests will include imaging scans. The stem cell transplant will be given through the central line.\n\nAfter discharge from the clinic, participants will have follow-up visits at least once per week for approximately 100 days. Then they will have follow-up clinic visits for 3 years.\n\nDonors, relatives, and healthy volunteers may provide samples of blood, stool, and saliva. Adults may also opt to provide samples of skin and bone marrow.",[28,29,30,31],"Core Binding Factor Alpha Subunits","Hematologic Neoplasms","Leukemia","Lymphoma",[33,34,35,36],"RUNX1","Haploidentical Hematopoietic Stem Cell Transplant","Germline RUNX1","germline RUNX1-aassociated myeloid malignancy","NOT_YET_RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":22},"2026-07-16",{"date":45,"type":22},"2036-06-01",{"name":47,"class":48},"National Cancer Institute (NCI)","NIH",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":49},"100053329","pre-malignant-states-to-hematologic-malignancies-in-firefighters-100053329","NCT06870760","Pre-malignant States to Hematologic Malignancies in Firefighters","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health information.\n2. Age ≥ 40-49 years at the time of consent (self-reported)\n3. Ability of the participant to understand and comply with study procedures for the entire length of the study\n4. Currently employed by Charlotte Fire Department (CFD) with at least 5 years on-the -job experience (self-reported)\n\nExclusion Criteria:\n\nAnyone with a current diagnosis of a hematologic malignancy will be excluded.",true,"40 Years","49 Years",{"count":60,"type":22},300,"OBSERVATIONAL","The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.",[64,65,66,30,67,68],"Clonal Hematopoiesis of Indeterminate Potential","Monoclonal Gammopathy","Non Hodgkin Lymphoma","Multiple Myeloma","Plasma Cell Disorder",[70,71,72],"Firefighters","CHIP","MGUS","RECRUITING",{"date":40,"type":41},{"date":76,"type":41},"2026-06-23",{"date":78,"type":22},"2027-04",{"name":80,"class":81},"Wake Forest University Health Sciences","OTHER",{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100054233","phase-2-dexamethasone-intravenous-injection-of-human-immunoglobulin-and-increased-infusion-of-mononuclear-cells-to-reduce-donor-specific-antibodies-in-haploid-hematopoietic-stem-cell-transplantation-a-prospective-multicenter-study-100054233","NCT07698080","Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploid Hematopoietic Stem Cell Transplantation: a Prospective, Multicenter Study","Inclusion Criteria:\n\n1. Diagnosis of benign or malignant hematological diseases (including leukemia, lymphoma, thalassemia, aplastic anemia, myelodysplastic syndromes, etc.) confirmed by NCCN guidelines, and determined by the investigator to require allogeneic hematopoietic stem cell transplantation.\n2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3.\n3. Donor-specific antibody (DSA) mean fluorescence intensity (MFI) \\> 500.\n4. Age between 18 and 65 years (age limits are also captured separately in the eligibility module).\n5. Body weight between 40 kg and 100 kg.\n6. No other suitable donor available (i.e., no DSA-negative related donor or unrelated donor).\n\nExclusion Criteria:\n\n1. Patients unsuitable for transplantation or without willingness to undergo transplantation, or diagnosed with non-hematological diseases.\n2. Estimated life expectancy \\\u003C 1 month.\n3. Known allergy to any drug or intervention used in the study regimen.\n4. Pregnancy, lactation, active severe infection, or severe major organ dysfunction.\n5. Severe psychiatric or neurological disorders that may affect the ability to provide informed consent and\u002For to report adverse events or comply with observation.\n6. Refusal or inability to sign the informed consent form.","18 Years","65 Years",{"count":91,"type":22},60,[25],"This study tests whether a combination of three treatments - dexamethasone (a steroid), intravenous immunoglobulin (IVIG, a protein that helps the immune system), and an extra dose of donor mononuclear cells - can safely lower harmful antibodies called donor-specific antibodies (DSA) in patients who need a stem cell transplant from a half-matched (haploidentical) family donor.\n\nIn these transplants, DSA are antibodies made by the patient's own body that attack the donor's stem cells. If DSA levels are high, the transplant is more likely to fail - the donor cells may not \"take\" (engraft). Currently, there is no single, simple, and reliable way to reduce DSA, and many existing methods have drawbacks.\n\nBased on our earlier experience in 11 patients, this three-part approach seemed to work well. All patients successfully engrafted, and DSA levels dropped quickly. Now we want to confirm these results in a larger, prospective, multicenter study.\n\nWe plan to enroll 60 patients aged 18-65 with blood cancers or other blood disorders who need a haploidentical transplant, have DSA levels above 500 MFI (a measure of antibody strength), and have no other suitable donor available. Participants will receive:\n\n* Dexamethasone (25 mg\u002Fm²) for 4 days before transplant,\n* IVIG (1 g\u002Fkg) one day before transplant,\n* Extra mononuclear cells on transplant day - the extra amount depends on how high their DSA level is (low, medium, or high).\n\nThe main goal is to see how many patients have primary graft failure (when the donor cells never engraft). We will also measure how long it takes for blood counts to recover, rates of graft-versus-host disease, survival, and side effects. All participants will be followed for 1 year.\n\nThis study will help us find out whether this combination is a safe, simple, and effective way to improve transplant success for patients with DSA who have no other donor options.",[30,31,95,96,97],"Thalassemia","Aplastic Anemia","Myelodysplastic Syndromes","2026-07-07",{"date":40,"type":41},{"date":101,"type":22},"2026-07-03",{"date":103,"type":22},"2028-07-03",{"name":105,"class":81},"Hematology department of the 920th hospital",{"id":107,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":26,"conditions":110,"keywords":111,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":116,"leadSponsor":117,"locationsCount":49},"100633272",{"count":21,"type":22},[25],[28,29,30,31],[33,34,35,36],"2026-07-01",{"date":114,"type":41},"2026-07-02",{"date":98,"type":22},{"date":45,"type":22},{"name":47,"class":48},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":49},"100547455","phase-1-autologous-cd22-car-t-cells-following-commercial-cd19-car-t-cells-in-b-cell-malignancies-100547455","NCT06408194","Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies","Phase I\u002FIb Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells Following Commercial CD19 CAR T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies","Inclusion Criteria:\n\n1. Diagnosis of histologically confirmed relapsed\u002Frefractory (R\u002FR) B cell acute lymphoblastic leukemia (ALL)\n2. Must be eligible to receive commercial KYMRIAH® (tisagenlecleucel) according to FDA approved package insert (refractory disease or in second or later relapse)\n3. CD19 and CD22 expression must be demonstrated on malignant cells by immunohistochemistry or flow cytometry. CD19 and CD22 expression at any level of expression will be acceptable, as that is the standard for commercial KYMRIAH® (tisagenlecleucel) and the optimal level of CD22 expression is not well defined.\n4. Age: ≥ 1 year of age and ≤ 25 years and 364 days of age at time of enrollment.\n5. Performance Status: Participants \\> 16 years of age: Karnofsky ≥ 50%; Participants ≤ 16 years of age: Lansky scale ≥ 50%.\n6. Normal Organ and Marrow Function\n\n   * Absolute Neutrophil Count (ANC) ≥ 750\u002FuL\\*\n   * Platelet count ≥ 50,000\u002FuL\\*\n   * Absolute Lymphocyte Count ALC \\> 150\u002FuL\\*\n   * Adequate renal, hepatic, pulmonary and cardiac function defined as:\n\n     * Baseline oxygen saturation \\> 92% on room air\n     * Creatinine within ULN for age or Creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 60 mL\u002Fmin\n     * Total bilirubin ≤ 1.5 mg\u002Fdl, except in Participants with Gilbert's syndrome. \\[Elevations related to leukemia involvement of the liver will not disqualify a subject\\]\n     * Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) ≤ 10 x ULN (except in Participants with liver involvement by leukemia)\n     * Cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an Echocardiogram.\n     * if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy); A subject will not be excluded because of pancytopenia ≥ Grade 3 if it is due to disease, based on the results of bone marrow studies.\n7. Participants with Central Nervous System (CNS) involvement or a history of CNS involvement are eligible only in the absence of neurologic symptoms that may mask or interfere with neurological assessment of toxicity\n8. Participants who have undergone autologous SCT with disease progression or relapse following SCT are eligible. Participants with history of allogeneic SCT must be at least 100 days from SCT, have no evidence of Graft versus Host Disease (GvHD), and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.\n9. Females of child bearing potential and males of child fathering potential must be willing to practice birth control during and for 4 months post chemotherapy or for as long as Chimeric Antigen Receptor (CAR) T cells are detectable in peripheral blood.\n10. Females of child bearing potential must have negative pregnancy test.\n11. Must meet wash out period since prior therapies according to commercial KYMRIAH® (tisagenlecleucel) SOPs.\n12. Must have recovered from acute side effects from prior therapy to meet eligibility.\n13. If had prior CAR therapy, will be eligible if at least 30 days has elapsed prior to apheresis.\n14. Ability to give informed consent. All Participants ≥ 18 years of age must be able to give informed consent. For participants \\\u003C18 years old their legal authorized representative (LAR) (i.e. parent or guardian) must give informed consent. Pediatric participants will be included in age appropriate discussion and assent per institutional SOPs will be obtained for those \\> 7 years of age, when appropriate. If a minor becomes of age during participation of this study, he\u002Fshe will be asked to reconsent as an adult.\n\n    * A subject will not be excluded because of pancytopenia ≥ Grade 3 if it is felt by the investigator to be due to underlying disease.\n\nExclusion Criteria:\n\n1. May not have Human Immunodeficiency Virus (HIV)\u002FHepatitis B (HBV) or Hepatitis C (HCV infection) or uncontrolled, symptomatic, intercurrent illness.\n2. May not have hyperleukocytosis (≥ 50,000 blasts\u002FμL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy.\n3. May not have severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study.\n4. May not have active CNS disorder, or history of MI, cardiac angioplasty or stenting, unstable angina or other clinically significant cardiac disease with 12 months of enrollment.\n5. May not have primary immunodeficiency or history of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression\u002Fsystemic disease modifying agents within the last 2 years.","1 Year","25 Years",{"count":128,"type":22},28,[130],"PHASE1","The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)\u002FRecommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusion of a commercial CAR called Tisagenlecleucel, to children and young adults with relapsed or refractory B-cell leukemia.",[30,133],"Acute Lymphoblastic Leukemia",[135,136,137,138],"KYMRIAH","CAR T","Tisagenlecleucel","Lymphodepletion",{"date":114,"type":41},{"date":141,"type":41},"2024-05-13",{"date":143,"type":22},"2026-07",{"name":145,"class":81},"Stanford University",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":17,"minAge":154,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":159,"conditions":160,"keywords":167,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":49},"100615412","halt-aging-in-survivors-of-blood-cancers-100615412","NCT07292272","Halt Aging in Survivors of Blood Cancers","Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study","HALTAging-1","Inclusion Criteria:\n\n1. Age ≥50 years\n2. A history of hematological malignancy\n3. Participants must be able to and willingly give informed consent\n\nExclusion Criteria:\n\n1. Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed.\n2. Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study.\n3. Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise.\n4. Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 \\\u003C10 ml\u002Fkg\u002Fmin).\n5. Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint).\n6. Self-reported pregnancy or the possibility of pregnancy.\n7. Participants who do not plan to follow up at the participating center.","50 Years",{"count":156,"type":22},180,[158],"NA","Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.",[161,30,162,67,163,164,165,166],"Hematological Malignancy","Lymphoid Leukemia","Myeloid Leukemia","Monocytic Leukemia","Non-hodgkin Lymphoma","Other Hematologic Condition",[168,30,162,67,163,164,165,166,169,170,171,172],"Hodgkin Lymphoma","Epigenetic clock","Biological aging","Quality of life","Blood cancer survivors","2026-06-29",{"date":112,"type":41},{"date":176,"type":41},"2026-04-09",{"date":178,"type":22},"2033-03-25",{"name":180,"class":81},"University of Nebraska",{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":56,"sex":17,"minAge":188,"maxAge":189,"enrollmentInfo":190,"targetDuration":192,"studyType":61,"phases":4,"briefSummary":193,"conditions":194,"keywords":243,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":260},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals","19 Years","110 Years",{"count":191,"type":22},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,30,234,235,236,67,237,238,239,240,241,242],"Pancreatic Cancer","Thyroid Cancer","Lung Cancer","Esophageal Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Anal Cancer","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Liver Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Kidney Cancer","Penile Cancer","Prostate Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Melanoma","Sarcoma","Unknown Primary Tumor","Ovarian Cancer","Endometrial Cancer","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[195,196,244,245,246,247,248,249,250,251,233,252,241,242],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":173,"type":41},{"date":256,"type":41},"2013-11-01",{"date":258,"type":22},"2099-12",{"name":180,"class":81},42,{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":270,"conditions":271,"keywords":278,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":441},"100143410","registry-of-older-patients-with-cancer-100143410","NCT01137825","Registry of Older Patients With Cancer","Carolina Senior: UNC Registry for Older Cancer Patients","DISEASE CHARACTERISTICS:\n\n* Patients must have an appointment at the North Carolina Cancer Hospital and agree to complete the Geriatric Assessment NOTE: Not all patients included in the registry will ultimately be diagnosed with cancer. Patients who complete a GA and are not diagnosed with cancer will remain in the database, but will be categorized into a separate group and will not have their medical records accessed.\n\nPATIENT CHARACTERISTICS:\n\n* Able to read and speak English\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified",{"count":269,"type":22},3000,"RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future.\n\nPURPOSE: This research study is gathering information from older patients with cancer into a registry.",[272,273,30,31,274,275,97,276,277],"Chronic Myeloproliferative Disorders","Cognitive\u002FFunctional Effects","Lymphoproliferative Disorder","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic\u002FMyeloproliferative Neoplasms","Unspecified Adult Solid Tumor, Protocol Specific",[279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432],"cognitive\u002Ffunctional effects","unspecified adult solid tumor, protocol specific","accelerated phase chronic myelogenous leukemia","acute undifferentiated leukemia","adult acute lymphoblastic leukemia in remission","adult acute myeloid leukemia in remission","adult acute myeloid leukemia with 11q23 (MLL) abnormalities","adult acute myeloid leukemia with inv(16)(p13;q22)","adult acute myeloid leukemia with t(15;17)(q22;q12)","adult acute myeloid leukemia with t(16;16)(p13;q22)","adult acute myeloid leukemia with t(8;21)(q22;q22)","atypical chronic myeloid leukemia, BCR-ABL negative","blastic phase chronic myelogenous leukemia","chronic myelomonocytic leukemia","chronic phase chronic myelogenous leukemia","mast cell leukemia","meningeal chronic myelogenous leukemia","progressive hairy cell leukemia, initial treatment","prolymphocytic leukemia","recurrent adult acute lymphoblastic leukemia","recurrent adult acute myeloid leukemia","recurrent adult T-cell leukemia\u002Flymphoma","refractory chronic lymphocytic leukemia","refractory hairy cell leukemia","relapsing chronic myelogenous leukemia","secondary acute myeloid leukemia","stage 0 chronic lymphocytic leukemia","stage I adult T-cell leukemia\u002Flymphoma","stage I chronic lymphocytic leukemia","stage II adult T-cell leukemia\u002Flymphoma","stage II chronic lymphocytic leukemia","stage III adult T-cell leukemia\u002Flymphoma","stage III chronic lymphocytic leukemia","stage IV adult T-cell leukemia\u002Flymphoma","stage IV chronic lymphocytic leukemia","T-cell large granular lymphocyte leukemia","untreated adult acute lymphoblastic leukemia","untreated adult acute myeloid leukemia","untreated hairy cell leukemia","recurrent adult Hodgkin lymphoma","stage I adult Hodgkin lymphoma","stage II adult Hodgkin lymphoma","stage III adult Hodgkin lymphoma","stage IV adult Hodgkin lymphoma","anaplastic large cell lymphoma","angioimmunoblastic T-cell lymphoma","cutaneous B-cell non-Hodgkin lymphoma","recurrent cutaneous T-cell non-Hodgkin lymphoma","stage I cutaneous T-cell non-Hodgkin lymphoma","stage II cutaneous T-cell non-Hodgkin lymphoma","stage III cutaneous T-cell non-Hodgkin lymphoma","stage IV cutaneous T-cell non-Hodgkin lymphoma","recurrent mycosis fungoides\u002FSezary syndrome","stage I mycosis fungoides\u002FSezary syndrome","stage II mycosis fungoides\u002FSezary syndrome","stage III mycosis fungoides\u002FSezary syndrome","stage IV mycosis fungoides\u002FSezary syndrome","adult grade III lymphomatoid granulomatosis","adult nasal type extranodal NK\u002FT-cell lymphoma","Waldenstrom macroglobulinemia","extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","nodal marginal zone B-cell lymphoma","splenic marginal zone lymphoma","contiguous stage II adult Burkitt lymphoma","contiguous stage II adult diffuse large cell lymphoma","contiguous stage II adult diffuse mixed cell lymphoma","contiguous stage II adult diffuse small cleaved cell lymphoma","contiguous stage II adult immunoblastic large cell lymphoma","contiguous stage II adult lymphoblastic lymphoma","contiguous stage II grade 1 follicular lymphoma","contiguous stage II grade 2 follicular lymphoma","contiguous stage II grade 3 follicular lymphoma","contiguous stage II mantle cell lymphoma","contiguous stage II marginal zone lymphoma","contiguous stage II small lymphocytic lymphoma","stage I adult Burkitt lymphoma","stage I adult diffuse large cell lymphoma","stage I adult diffuse mixed cell lymphoma","stage I adult diffuse small cleaved cell lymphoma","stage I adult immunoblastic large cell lymphoma","stage I adult lymphoblastic lymphoma","stage I grade 1 follicular lymphoma","stage I grade 2 follicular lymphoma","stage I grade 3 follicular lymphoma","stage I mantle cell lymphoma","stage I marginal zone lymphoma","stage I small lymphocytic lymphoma","noncontiguous stage II adult Burkitt lymphoma","noncontiguous stage II adult diffuse large cell lymphoma","noncontiguous stage II adult diffuse mixed cell lymphoma","noncontiguous stage II adult diffuse small cleaved cell lymphoma","noncontiguous stage II adult immunoblastic large cell lymphoma","noncontiguous stage II adult lymphoblastic lymphoma","noncontiguous stage II grade 1 follicular lymphoma","noncontiguous stage II grade 2 follicular lymphoma","noncontiguous stage II grade 3 follicular lymphoma","noncontiguous stage II mantle cell lymphoma","noncontiguous stage II marginal zone lymphoma","noncontiguous stage II small lymphocytic lymphoma","stage III adult Burkitt lymphoma","stage III adult diffuse large cell lymphoma","stage III adult diffuse mixed cell lymphoma","stage III adult diffuse small cleaved cell lymphoma","stage III adult immunoblastic large cell lymphoma","stage III adult lymphoblastic lymphoma","stage III grade 1 follicular lymphoma","stage III grade 2 follicular lymphoma","stage III grade 3 follicular lymphoma","stage III mantle cell lymphoma","stage III marginal zone lymphoma","stage III small lymphocytic lymphoma","stage IV adult Burkitt lymphoma","stage IV adult diffuse large cell lymphoma","stage IV adult diffuse mixed cell lymphoma","stage IV adult diffuse small cleaved cell lymphoma","stage IV adult immunoblastic large cell lymphoma","stage IV adult lymphoblastic lymphoma","stage IV grade 1 follicular lymphoma","stage IV grade 2 follicular lymphoma","stage IV grade 3 follicular lymphoma","stage IV mantle cell lymphoma","stage IV marginal zone lymphoma","stage IV small lymphocytic lymphoma","recurrent adult Burkitt lymphoma","recurrent adult diffuse large cell lymphoma","recurrent adult diffuse mixed cell lymphoma","recurrent adult diffuse small cleaved cell lymphoma","recurrent adult grade III lymphomatoid granulomatosis","recurrent adult immunoblastic large cell lymphoma","recurrent adult lymphoblastic lymphoma","recurrent grade 1 follicular lymphoma","recurrent grade 2 follicular lymphoma","recurrent grade 3 follicular lymphoma","recurrent mantle cell lymphoma","recurrent marginal zone lymphoma","recurrent small lymphocytic lymphoma","intraocular lymphoma","post-transplant lymphoproliferative disorder","chronic eosinophilic leukemia","chronic neutrophilic leukemia","primary myelofibrosis","essential thrombocythemia","polycythemia vera","extramedullary plasmacytoma","isolated plasmacytoma of bone","stage I multiple myeloma","stage II multiple myeloma","stage III multiple myeloma","primary systemic amyloidosis","refractory multiple myeloma","de novo myelodysplastic syndromes","previously treated myelodysplastic syndromes","secondary myelodysplastic syndromes","myelodysplastic\u002Fmyeloproliferative neoplasm, unclassifiable","2026-06-24",{"date":173,"type":41},{"date":436,"type":4},"2009-09",{"date":438,"type":22},"2030-12",{"name":440,"class":81},"UNC Lineberger Comprehensive Cancer Center",7,{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":449,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":452,"briefSummary":453,"conditions":454,"keywords":461,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":472},"100620325","phase-1-a-study-of-revumenib-and-mezigdomide-in-people-with-leukemia-100620325","NCT07356154","A Study of Revumenib and Mezigdomide in People With Leukemia","A Phase 1\u002F2 Study of the Menin Inhibitor Revumenib With the CELMod Mezigdomide in Relapsed\u002FRefractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged Acute Leukemias","Inclusion Criteria:\n\n* Participant must be ≥ 12 years of age at the time of signing the informed consent form (ICF).\n* Participant must weigh at least 40 kg\n* Participant is willing and able to adhere to the study visit schedule and other protocol requirements.\n* Participant has relapsed\u002Frefractory acute leukemia defined acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia after as failure of at least 1 prior line of therapy (can be either primary refractory disease or progression during or after treatment)\n* Participant has confirmed acute leukemia with detectable NPM1c, KMT2A translocation, or NUP98 translocation.\n\n  1. At MSK, NPM1 testing utilizes MSK-REACT, a rapid multi-gene NGS panel used in all new AML diagnoses that is clinically validated by the Laboratory of Diagnostic Molecular Pathology pursuant to the requirements of CLIA'88 and approved by New York State, or MSK-IMPACT, a multi-gene NGS panel, which is authorized by the FDA. At non-MSK sites, NPM1 testing may be performed in local CLIA-certified laboratories using validated clinical assays with capable of detecting NPM1c variants at a frequency of ≥5%. Eligible patients must have an NPM1c (nucleophosmin) exon 12 variant as determined by these assays.\n  2. At MSK, KMT2A and NUP98 testing will utilize chromosomal analysis and fluorescence in situ hybridization studies. At non-MSK sites, testing may be performed in local CLIA-certified laboratories using validated clinical assays with performance characteristics sufficient to detect relevant translocations. Eligible patients must have a KMT2A or NUP98 translocation as determined by these assays\n  3. The patient's chart will be utilized for screening purposes\n* Regarding prior treatment with a menin inhibitor:\n\n  1. Participants enrolled in Phase 1 have no requirements regarding prior treatment with a menin inhibitor\n  2. Participants enrolled in Phase 2, cohort 1, are required to be menin inhibitor naïve (no previous treatment with a menin inhibitor)\n  3. Participants enrolled in Phase 2, cohort 2, are required to be menin inhibitor exposed (previous treatment received a menin inhibitor)\n* Regarding prior alloSCT, at 60 days must have elapsed from day of transplant and at least 4 weeks must have elapsed from first dose of donor lymphocyte infusion.\n* Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score 0-2 (if aged ≥18 years); Karnofsky Performance Scale of ≥50 (if aged ≥16 years and \\\u003C18 years); Lansky Performance Score of ≥50 (if aged \\\u003C16 years).\n* Participant must have a WBC count \\\u003C25,000\u002FμL at the time of initiation of study drug (leukapheresis may be performed and\u002For hydroxyurea may be administered to decrease the WBC count to \\\u003C25,000\u002FμL).\n* Participant has adequate organ function defined as:\n\n  1. Serum aspartate aminotransferase\u002Fserum glutamic oxaloacetic transaminase (AST\u002FSGOT) and alanine aminotransferase (ALT\u002FSGPT) ≤ 3 x ULN, unless considered due to leukemic organ involvement.\n  2. Serum total bilirubin \\\u003C 1.5 x ULN. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis, leukemia organ involvement or Gilbert's syndrome.\n  3. Serum creatinine \\\u003C 2 x ULN or estimated glomerular filtration rate 60 mL\u002Fmin or greater based on local institutional practice for age-appropriate determination (e.g, Schwartz formula for pediatric patients or Cockcroft Gault formula for adults).\n  4. Adequate cardiac function defined as ejection fraction of ≥ 50% by echocardiogram or multigated acquisition scan.\n\nExclusion Criteria:\n\n* Participants with acute promyelocytic leukemia\n* Participants with isolated myeloid sarcoma\n* Participants who have previously received mezigdomide.\n* Participants with immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, disseminated intravascular coagulation, or uncontrolled tumor lysis syndrome.\n* Participant has presence of any other condition that may increase the risk associated with study participation, and in the opinion of the treating investigator, would make the patient inappropriate for entry into the study.\n* Participants with concurrent other malignancy that will confound interpretation of study endpoints.\n* Participants who have received other anti-leukemia therapy within 5 half-lives of the agent or 14 days, whichever is sooner, prior to study treatment and if toxicity related to said agent has not resolved; exceptions of acceptable concomitant therapies are listed below\n\n  1. Concomitant cytoreductive therapy in the form of hydroxyurea, corticosteroids, or cytarabine is permitted.\n  2. Concomitant therapy in the form of intrathecal chemotherapy for CNS treatment, is permitted.\n  3. Radiation therapy is not permitted except for localized palliative radiation to focal lesions after discussion with the Medical Monitor for patients who have progressed but remain on the study due to perceived clinical benefit per Investigator assessment\n* Participants with active graft versus host disease (GVHD) of grade 2 or higher requiring systemic treatment. Skin GVHD solely managed with topical corticosteroids would not be exclusionary.\n* Participant has significant active cardiac disease within 6 months prior to start of study treatment, including New York Heart Association (NYHA) class III or IV congestive heart failure; acute coronary syndrome (ACS); and\u002For stroke.\n* Participant has QTc interval (i.e., Fridericia's correction \\[QTcF\\]) ≥ 450 ms (mean of triplicate ECG) or other factors that increase the risk of QT prolongation or ventricular arrhythmic events (e.g., family history of long QT interval syndrome). Patients with a QTcF over 450 ms due to a bundle branch block or a pacemaker may participate in the study with approval of the study principal investigator.\n* Participant has active viral infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)\n* Participant is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.\n* Participant has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and\u002For other treatment).\n* Participant with active use of strong or moderate CYP3A4 inhibitors or strong CYP3A4 inducers. Details reviewed in Appendix B.\n* Participant with use of proton pump inhibitors less than 2 weeks prior to initiating treatment\n* Female participant who is pregnant or lactating. Male or female participants not willing to comply with contraceptive requirements, which include 4 months of contraception after last dose of revumenib for males and 6 months for females. Additional contraception details reviewed in Appendix D.","12 Years",{"count":451,"type":22},52,[130,25],"The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.",[30,455,456,457,458,459,133,460],"Acute Leukemia","Relapse Leukemia","Refractory Leukemia","Refractory Acute Leukemia","Acute Myeloid Leukemia","Mixed Phenotype Acute Leukemia",[30,455,456,457,458,459,133,460,462,463],"Memorial Sloan Kettering Cancer Center","25-229","2026-06-18",{"date":466,"type":41},"2026-06-22",{"date":468,"type":41},"2026-01-16",{"date":470,"type":22},"2029-01-16",{"name":462,"class":81},10,{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":485,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":500},"100579428","phase-2-evaluation-of-two-dose-levels-of-quizartinib-as-maintenance-in-flt3-itd--acute-myeloid-leukemia-patients-in-complete-remission-100579428","NCT06824168","Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission","Key Inclusion Criteria:\n\n1. Adults ≥18 years of age or the minimum legal adult age (whichever is greater) on the day of signing the ICF (no upper limit of age).\n2. Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm based on the World Health Organization (WHO) 2008\u002F2016 classification.\n3. Participant has confirmed FLT3-ITD-positive (≥0.05 SR or ≥5% VAF) activating mutation from initial diagnosis in bone marrow or peripheral blood as determined by a local institution's validated molecular testing.\n4. Participants must have confirmed, morphologically documented CR1, on the most recent BMA, based on the local laboratory results, performed within 28 days prior to C1D1 of maintenance therapy. Complete remission will be defined as \\\u003C5% blasts in the bone marrow with no morphologic characteristics of acute leukemia (e.g., Auer Rods), no evidence of extramedullary disease, and no leukemic blasts in the peripheral blood.\n\n   Complete blood count recovery is required with absolute neutrophil count of more than 1.000 × 109\u002FL and platelets more than 100 × 109\u002FL (IWG criteria).27\n5. Participant must meet the following prior therapy requirements:\n\n   1. Has received at least one cycle of induction therapy but no more than two to achieve CR1. The induction cycles can be the same regimen or different regimens and may contain conventional agents only (e.g., cytarabine + daunorubicin or idarubicin: \"7 + 3\" or \"5 + 2\"), or a combination with FLT3 inhibitors.\n   2. Has not received more than four cycles of consolidation therapy. Regimens may contain conventional agents only.\n   3. FLT3 inhibitors are permitted as part of the induction or consolidation treatment.\n\n   Participants who received FLT3 inhibitors before enrollment in the trial will need a washout period of 14 days.\n6. Able to begin the maintenance phase within 60 days of D1 of the last consolidation cycle received.\n7. Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2.\n\nKey Exclusion Criteria:\n\n1. Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or BCR-ABL positive leukemia (i.e., chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).\n2. Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms.\n3. Prior treatment for AML, except for the following allowances:\n\n   1. Induction and consolidation therapy, as previously described (inclusion criterion #5)\n   2. Leukapheresis\n   3. Hydroxyurea to treat hyperleukocytosis\n   4. Cranial radiotherapy for central nervous system (CNS) leukostasis\n   5. Prophylactic intrathecal chemotherapy\n   6. Growth factor\u002Fcytokine support\n4. Participant had received allo-HSCT as part of AML treatment.\n5. Treatment with any strong or moderate CYP3A inducers within 2 weeks or 5 half-lives of randomization whichever is longer\n6. Uncontrolled or significant cardiovascular disease, including the following:\n\n   1. QTcF interval \\>450 ms (based on average of triplicate ECG at Screening)\n   2. Diagnosed or suspected congenital long QT syndrome or known family history of congenital long QT syndrome\n   3. History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes\n   4. Participant has bradycardia of less than 50 beats per minute (bpm; as determined by central reading), unless the participant has a pacemaker\n   5. History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.\n   6. Myocardial infarction within 6 months prior to screening\n   7. Uncontrolled angina pectoris within 6 months prior to screening\n   8. New York Heart Association Class 3 or 4 congestive heart failure\n   9. LVEF ≤45% or institutional lower limit of normal\n   10. Uncontrolled hypertension (resting systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg despite optimal medical management)\n   11. Complete left or right bundle branch block\n   12. Severe aortic stenosis",{"count":481,"type":22},130,[25],"This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction\u002Fconsolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).",[459,30],[486,487,488,489,490],"acute myeloid leukemia","quizartinib","FLT3","allo-HSCT","leukemia","2026-06-17",{"date":466,"type":41},{"date":494,"type":41},"2025-07-18",{"date":496,"type":22},"2032-07-14",{"name":498,"class":499},"Daiichi Sankyo","INDUSTRY",58,{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":56,"sex":17,"minAge":508,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":510,"conditions":511,"keywords":512,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":522},"100457545","cognitive-aftereffects-of-neurotoxicity-in-children-and-young-adults-with-relapsedrefractory-hematologic-malignancies-who-receive-car-t-cell-therapy-100457545","NCT05237986","Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed\u002FRefractory Hematologic Malignancies Who Receive CAR T-cell Therapy","Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed\u002FRefractory Hematologic Malignancies Who Receive CAR T-cell Therapy","* INCLUSION CRITERIA:\n* Participants with disease\n\n  * Participants are diagnosed with relapsed\u002Frefractory leukemias or lymphomas, and are scheduled to receive CAR T-cell treatment in one of the enrolling sites\n  * For participants enrolled on a CAR T-cell treatment protocol, data sharing for the purposes of this study must be allowed.\n  * Age \\>= 5 and \\\u003C=35 years old\n  * Participant must have an eligible caregiver (informant) who is willing to complete assessments about the participant of this study\n  * Participants (\\\u003C18 years, or \\>=18 years if needed) must have an eligible caregiver to assist with setting up an appropriate test environment for the remote evaluations\n  * Participant must be able to speak and understand English or Spanish\n  * Participants must have access to a computer or tablet with a camera and an internet connection\n  * Participant or parent\u002Fguardian must be able to understand and willing to sign a written consent document\n* Caregivers (informants)\n\n  * Participants must be able to speak and read in English or Spanish\n  * Participants who are caregivers for participants with disease addressed above\n  * Age \\>= 18 years old\n  * Participants must have access to a computer or tablet\n  * Participants (of children \\\u003C18 years, or \\>18 years if needed) must be willing to help set up an appropriate test environment for the remote evaluations\n  * Participant is able to understand and willing to sign a written consent document\n\nEXCLUSION CRITERIA:\n\n-Participants with disease who have a pre-existing global intellectual disability (e.g., Down Syndrome)","5 Years",{"count":91,"type":22},"Background:\n\nCAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically interested in learning if and how this treatment may affect the brain or your thinking skills.\n\nObjective:\n\nTo learn if CAR T-cell therapy can affect how children and adults think, process, and remember things.\n\nEligibility:\n\nPeople aged 5-35 who have blood cancer that has not responded to treatment, or the blood cancer has come back after treatment, and who will receive CAR T-cell therapy. Caregivers are also needed. All participants must be able to speak and read in English or Spanish.\n\nDesign:\n\nParticipants will be screened with a medical history.\n\nInformation from participants medical records will be collected.\n\nParticipants will take tests at home or at NIH to see how well they think, read, learn, remember, reason, and pay attention. The tests will be both computerized and paper\u002Fpencil. They will take less than 1 hour to complete.\n\nParticipants and a parent\u002Fadult observer will complete a 5-minute Background Information Form and a checklist of nervous system symptoms.\n\nIf participants are 5 years or older, they will participate in activities to test their ability to do different thinking tasks, like answer questions, complete puzzle patterns, and remember things.\n\nParticipants and their caregivers will complete questions to see if they are having specific symptoms related to receiving CAR T-cells. The questions will assess their well-being and needs. The questions will take less than 1 hour to complete.\n\nSome tests and questions will be repeated at different time points in the study.\n\nParticipation will last for up to 3 years.",[31,30],[513,514,30,31,515],"Cogstate","Memory","Natural History",{"date":464,"type":41},{"date":518,"type":41},"2025-06-23",{"date":520,"type":22},"2028-12-01",{"name":47,"class":48},3,{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":23,"phases":532,"briefSummary":533,"conditions":534,"keywords":538,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":549},"100526733","phase-1-preemptive-ciml-nk-cell-therapy-after-hematopoietic-stem-cell-transplantation-100526733","NCT06138587","Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation","Cytokine-induced Memory-like Natural Killer Cell Therapy After Hematopoietic Stem Cell Transplantation for Eradication of Measurable Residual Disease, a Phase I\u002FIb Clinical Trial","Inclusion Criteria for Trial Enrollment:\n\n* Histologically or cytologically confirmed diagnosis of AML, MDS, or MDS\u002FMPN that is at high risk for post-transplant relapse and that has measurable disease prior to transplant. Patients at high risk for post-transplant relapse include:\n\n  * De novo AML diagnosed at or after age 60, except CBF AML\n  * De novo AML in CR1 AND MRD+ by Hematologics Inc. flow cytometry pretransplant (this would be on the most recent pre-transplant bone marrow)\n  * Secondary AML\n  * AML with 5 - \\> 10% blasts at the time of transplant who are judged by their treating clinician and study PI to have no benefit from additional pre-transplant chemotherapy\n  * Any AML transplanted in CR2 or greater\n  * TP53-mutated MDS or AML\n  * Therapy-related MDS or AML\n  * MDS with monosomy 7\n  * MDS with \\>= 5% blasts at the time of transplant\n  * MDS\u002FMPN or CMML\n* Adequate organ function within 2 weeks of NK cell infusion as defined below (should correspond with admission for SCT):\n\n  * Total bilirubin: ≤1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease related hemolysis, then \\\u003C 3 x ULN)\n  * AST(SGOT)\u002FALT(SGPT): ≤3 x institutional ULN\n  * Serum creatinine \\\u003C\u002F= 2.0mg\u002FdL\n  * O2 saturation: ≥90% on room air\n  * LVEF \\>40%. If there is no clinical evidence of a change in cardiovascular function from the time of pre-transplantation ECHO (per FACT standards should be performed within 6 weeks of stem cell infusion), then there is no need to repeat it. Otherwise, an ECHO will need to be repeated.\n* Adult patients (age ≥ 18) eligible for and planned to undergo a standard-of-care reduced intensity conditioning (RIC) HLA-matched related or related haploidentical allogeneic stem cell transplant using PTCY-based GVHD prophylaxis. All eligibility criteria and workups for undergoing SOC allogeneic SCT for the recipient and donor will be based on institutional standards and SOPs.\n* For patients with AML, the disease must meet criteria for CR\u002FCri according to 2017 ELN guidelines, or have 5-10% blasts at the time of the transplant and in the judgement of their primary BMT clinician and study PI to have no benefit from additional pre-transplant chemotherapy. For patients with MDS or MDS\u002FMPN, the blast percentage on the bone marrow aspirate and biopsy must be less than 10%.\n* The same related donor is available to provide a non-mobilized apheresis product after the stem-cell donation.\n* ECOG performance status \\\u003C= 2 (Karnofsky \\>= 60%, see Appendix C).\n* Negative pregnancy test for women of childbearing age\n* The effects of CIML NK cells combined with IL-2 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after IL-2 dose administration.\n* No laboratory evidence of ongoing hemolysis in opinion of investigator\n\nExclusion Criteria Trial Enrollment:\n\n* Adult participants who are eligible for and who would be expected to have a greater benefit from myeloablative conditioning in their SOC allo HSCT as judged by their treating physician\n* Participants with mutations such as FLT3-ITD, IDH, or BCR-ABL mutations who are planned to receive targeted agent maintenance therapy to prevent relapse post-transplant are excluded.\n* Extramedullary leukemia involving sanctuary sites not readily accessible to immune surveillance, such as CNS or testis. Other sites of extramedullary relapse (e.g., leukemia cutis, granulocytic sarcoma) are acceptable.\n* The planned use of sirolimus for GVHD prophylaxis would result in exclusion of the patient from the study. Consideration of the addition of sirolimus to the GVHD prophylaxis regimen within the first 100 days after transplant must be reviewed with the study PI.\n* Prior history of allogeneic stem cell transplant other than SOC alloHSCT referred to in this study taking place 7 days prior to CIML NK infusion.\n* Prior history of solid organ (allograft) transplantation\n* Prior history of allergic reactions to cellular products\n* Uncontrolled concurrent illness such as ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric\u002Fsocial illness that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because of the unknown teratogenic risk of CIML NK cells and IL-2 and with the potential for teratogenic or abortifacient effects by Flu\u002FCy chemotherapy regimen. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CIML NK cells and IL-2, breastfeeding should be discontinued if the mother is treated on this study.\n* HIV-positive patients are excluded due to the potential for interaction between antiretroviral therapy as well as the risk for lethal infection in the context of marrow-suppressive therapy.\n* Patients with active and uncontrolled Hepatitis B or C are ineligible due to the high risk of treatment-related hepatotoxicity after cellular therapy.\n* Individuals with a history of a different malignancy are ineligible except for the following circumstances: 1. History of other malignancy and have had complete remission of disease for at least 2 years; 2. Diagnosed and treated within the past 2 years for: nonmetastatic melanoma, surgically resected (not needing systemic chemotherapy) squamous cell carcinoma of skin and nonmetastatic prostate cancer not needing systemic chemotherapy.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to IL-2 or other agents used in study. 3. Diagnosed with MGUS or smoldering myeloma, and\u002For treated for multiple myeloma or plasmacytoma as long as attainment of complete remission by IMWG criteria following therapy.\n* Prior history of Grade 2 or higher hemolytic anemia (\\>\u002F= 2g decrease in hemoglobin plus laboratory evidence of hemolysis) from any cause.\n\nInclusion Criteria to Receive CIML NK Infusion\n\n* Adequate organ function within 24 hours of NK cell infusion as defined below:\n\n  * Total bilirubin: ≤1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then \\\u003C 3 x ULN)\n  * AST(SGOT)\u002FALT(SGPT): ≤3 x institutional ULN\n  * Grade ≥3 non-hematologic toxicities of cyclophosphamide and fludarabine conditioning (except for Grade 3 nausea, vomiting, diarrhea, or constipation).\n* No significant change in clinical status that would, in the opinion of the investigator, increase the risk of adverse events associated with CIML NK infusion, (e.g., symptomatic congestive heart failure, unstable angina, cardiac arrhythmia)\n* No evidence of ongoing hemolysis in opinion of investigator\n\nExclusion Criteria to Receive CIML NK Infusion:\n\n* Systemic steroid therapy (oral or IV) on the day of NK cell infusion\n* Uncontrolled concurrent illness such as ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric\u002Fsocial illness that would limit compliance with study requirements.\n* Participants who have had other investigational agents within 4 weeks prior to CIML NK cell infusion (6 weeks for nitrosoureas or mitomycin C), or immunotherapy within 8 weeks prior, or those who have not recovered from adverse events due to agents administered more than 4 weeks prior. Therapy with BCR-ABL inhibitors must be stopped at least 2 weeks before CIML NK cell infusion and may not be resumed during the DLT period. The use of tocilizumab for cytokine release syndrome after stem cell infusion does not exclude patients, but the use of steroids for the treatment of CRS excludes patients if they are still on steroids by the day of planned NK cell infusion.\n* Systemic steroid use of \\>10mg\u002Fday of prednisone equivalent is an exclusion criteria unless there is a plan for dose to be tapered below this limit within 4 weeks prior to NK cell infusion.\n\nPatients must be off systemic steroid therapy on the day of planned NK cell infusion.\n\n-The presence of donor-specific antibodies (DSAs) with mean fluorescence intensity (MFI) \\>1000 using a standard assay who do not receive a desensitization protocol prior to and during stem cell transplant, or else who do receive a desensitization protocol and have detectable DSAs +1 day after stem cell infusion.\n\nIf inclusion\u002Fexclusion criteria are not met on planned day of CIML NK cell infusion, the NK cell infusion may be delayed for up to 48 hours to enable inclusion criteria to be met.\n\nHowever, patient may still receive CIML NK infusion if relevant parameters are reviewed and both PI and IND holder are in agreement with proceeding.",{"count":531,"type":22},15,[130],"The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant.\n\nNames of the study therapies involved in this study are:\n\n* CIML NK cells intravenous infusion (cellular therapy)\n* Subcutaneous Interleukin-2 (recombinant, human glycoprotein)",[459,30,535,97,536,537],"Leukemia, Myeloid","Myeloproliferative Neoplasm","Myeloproliferative Disorders",[459,30,535,539,540],"Myelodysplastic Syndrome","MDS and Myeloproliferative Neoplasm Overlap Syndrome","2026-06-15",{"date":491,"type":41},{"date":544,"type":41},"2024-01-24",{"date":546,"type":22},"2027-11-30",{"name":548,"class":81},"Dana-Farber Cancer Institute",2,{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":522},"100470233","marathon-of-hope-cancer-centres-network-study-for-ontario-mohccn-o-100470233","NCT05403177","Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)","MOHCCN-O","Inclusion Criteria:\n\n1. Patients with histological and\u002For cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy\n2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:\n\n   1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)\n   2. Have sufficient biospecimens (tumor and\u002For blood samples) available for more comprehensive molecular and immunophenotypic characterization\n3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.\n4. Participating patients must agree to share their anonymized clinical and genomic data\n\nExclusion Criteria:\n\nNone.",{"count":558,"type":22},500,"The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients",[233,561,562,214,216,563,564,30,31,197,234,565],"Colorectal Cancer","Pancreas Cancer","Ovary Cancer","Head and Neck Cancer","Solid Tumor","2026-06-09",{"date":568,"type":41},"2026-06-10",{"date":570,"type":41},"2022-06-23",{"date":572,"type":22},"2030-10",{"name":574,"class":81},"University Health Network, Toronto",{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":56,"sex":17,"minAge":582,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":23,"phases":585,"briefSummary":586,"conditions":587,"keywords":590,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":601,"leadSponsor":603,"locationsCount":49},"100643735","strength-training-exercise-in-pediatric-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma-step-all-100643735","NCT07634653","Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)","STEP-ALL","Inclusion Criteria for children:\n\nAll subjects must meet the following criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. OR Written assent and parental\u002Flegal guardian consent.\n* Age \\>= 6 and \\\u003C =21 years at the time of diagnosis.\n* Newly- diagnosed with one of the following diseases: B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma\n\nExclusion Criteria for children:\n\n* Subjects must not be receiving any investigational or additional anti-cancer medicines during induction.\n* Significant concurrent disease, illness, or psychiatric disorder or social issue that would compromise subject safety or adherence to the protocol treatment or procedures, interfere with consent, study participation, follow-up, or interpretation of the study results.\n\nOptional caregiver participation:\n\nInclusion Criteria :All caregivers must meet the following criteria\n\n* Written informed consent to participate in the caregiver interviews.\n* The caregiver must be a parent or legal guardian ≥ 18 years old, and their child must be \\\u003C18 years","6 Years",{"count":584,"type":22},40,[158],"Acute lymphoblastic leukemia (ALL) is the most common cancer in children and, along with lymphoblastic lymphoma, represents the most common group of childhood lymphoid malignancies. Survival rates have improved over the years, but many children still experience long-term side effects from treatment. These can include tiredness, weak muscles, pain, nerve problems, difficulty moving, and other physical challenges. Many children with ALL are also overweight at diagnosis, and weight gain often continues during treatment. As a result, about half of childhood leukemia survivors have a BMI at or above the 85th percentile.\n\nTreatment decisions are usually based on a child's symptoms and genetic risk factors. However, some risk factors such as physical activity can be modified. Exercise during treatment may help children feel better and may even improve survival. However, research on early symptom tracking and structured exercise during the first phase of chemotherapy is limited, uses different methods, and often does not include reliable patient-reported symptoms.\n\nEffective exercise programs for children with ALL and lymphoblastic lymphoma need to consider the child's age, treatment side effects, motivation, family support, and ways to encourage long-term behavior change. Because children spend little time in the hospital during the induction phase, a mix of in-person and virtual sessions supported by real-time Zoom instruction can make it possible to offer safe and supervised exercise at home.\n\nThis study will use a guided exercise plan that includes tools to track sets, repetitions, intensity, warm-up time, and perceived exertion. These tools help with consistent monitoring and support both patients and caregivers throughout the program. Twenty children newly diagnosed with ALL or lymphoblastic lymphoma who receive standard 3-4 drug induction chemotherapy will be invited to participate. Our goal is to determine whether a 9-week hybrid exercise program, combined with weekly symptom check-ins, is practical and achievable in both hospital and home settings.",[30,455,588,589,133],"Acute Lymphoid Leukemia","Lymphoblastic Lymphoma",[591,592,593,594,595,596,597],"children","pediatric","weight gain","body mass index (BMI)","physical activity","Exercise","hybrid exercise program","2026-06-08",{"date":568,"type":41},{"date":598,"type":22},{"date":602,"type":22},"2028-06-01",{"name":440,"class":81},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":56,"sex":17,"minAge":612,"maxAge":613,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":616,"briefSummary":618,"conditions":619,"keywords":624,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":49},"100565518","early-phase-1-exercise-as-an-immune-adjuvant-for-allogeneic-cell-therapies-100565518","NCT06643221","Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","Exercise-induced Adrenergic Receptor Signaling as an Immune Adjuvant for Allogeneic Cell Therapies","Allo-X","Procedures are in place for protecting against or minimizing the risks to the healthy volunteers recruited for this study. Physical risk to volunteers and matched related donors will be protected through health screening to determine study eligibility, and medical monitoring with an established test termination criterion during the exercise and isoproterenol infusion trials.\n\nTo protect against the remote risk of an adverse cardiac event occurring during exercise and isoproterenol infusion, the study will only enroll volunteers who are considered \"low risk\" for maximal stress testing in accordance with the guidelines published by the American College of Sports Medicine (ACSM) and American Heart Association (AHA). Individuals who are considered \"low risk\" are men and women who are asymptomatic and have no more than one risk factor for cardiovascular disease (CVD). The risks to subjects are therefore extremely low. All infusions will take place in the Clinical and Translational Sciences Research Center (CATS) Infusion Suite, which is a designated University of Arizona campus facility for infusion trials and equipped with appropriate medical personnel and monitoring equipment (i.e. ECG). The graded exercise tests and isoproterenol infusions procedures will be performed under the direction of a licensed and board-certified cardiologist\n\nInclusion Criteria:\n\nParticipants must:\n\n* Be between 21 and 55 years of age.\n* Be classified as 'low-risk' for graded exercise\u002Fstress testing according to ACSM-AHA criteria.\n* Have no contraindications for the use of isoproterenol, carvedilol, bisoprolol, nadolol, or roflumilast as per FDA guidelines.\n\nExclusion Criteria:\n\nParticipants will be excluded if they:\n\n* Currently use tobacco products or have quit within the last 6 months.\n* Have a body mass index (BMI) greater than 34 kg\u002Fm² or waist circumference exceeding 102 cm for men and 88 cm for women.\n* Use any medications known to affect the immune system or regularly take ibuprofen\u002Faspirin, antidepressants, or medications that alter blood pressure or cardiovascular function.\n* Use of hormone replacement therapy.\n* Are pregnant or breastfeeding.\n* Have chronic or debilitating arthritis or have been bedridden in the past three months.\n* Experienced a common illness (e.g., colds) within the past 6 weeks.\n* Have central or peripheral nervous disorders, a history of stroke, or major affective disorder.\n* Are infected with HIV or hepatitis or have any autoimmune disease.\n* Have known cardiovascular disease or contraindications for the use of isoproterenol, carvedilol, bisoprolol, nadolol, or roflumilast.\n* Use any prescription medications or have an allergy to beta-blockers.\n* Have a resting heart rate of less than 50 beats per minute.\n* Suffer from asthma, emphysema, bronchitis, kidney disease, pheochromocytoma, diabetes, overactive thyroid, or a history of severe anaphylactic reactions.\n* Are scheduled for surgery.\n\nAdditionally, participants who meet the inclusion criteria but present with more than one of the following cardiovascular disease (CVD) risk factors will be excluded unless cleared by a cardiologist:\n\n* Family History: Myocardial infarction, coronary revascularization, or sudden death before 55 years of age in a father or male first-degree relative, or before 65 years of age in a mother or female first-degree relative.\n* Hypertension: Systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg.\n* Dyslipidemia: Total serum cholesterol exceeding 200 mg\u002Fdl.\n* Pre-diabetes: Fasting blood glucose levels between 100 mg\u002Fdl and 126 mg\u002Fdl.","21 Years","55 Years",{"count":615,"type":22},200,[617],"EARLY_PHASE1","This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a cancer patient, usually to help prevent or treat cancer relapse after a stem cell transplant. These donor cells can either be directly infused into the patient or grown in a lab to create more specialized immune cells that target and kill cancer. While this therapy has been helpful for many patients, there is a need to make it more effective for a larger group and reduce side effects like graft-versus-host disease (GvHD), where the donor's immune cells attack the patient's healthy tissue.\n\nThis Early Phase 1 trial will test whether exercise can help produce better immune cells from donors. The investigators will recruit healthy participants for three study groups:\n\n1. Exercise Group: Participants will complete a 20-minute cycling exercise session. The investigators will collect blood samples before, during, and after exercise to study the number and quality of immune cells. The investigators will also use the collected cells to create immune therapies and test their ability to kill cancer cells in the lab and control cancer growth in mice.\n2. Exercise and Beta Blocker Group: In this group, participants will complete up to five cycling sessions, with at least a week between each session. Before each session, participants will take either a placebo or a drug (beta blocker) that blocks stress hormones like adrenaline. The investigators will collect blood samples before and during exercise to see how blocking these hormones changes the effect of exercise on immune cells.\n3. Isoproterenol Group: Participants in this group will receive a 20-minute infusion of isoproterenol, a drug that mimics the effects of adrenaline. The investigators will collect blood samples before, during, and after the infusion to see if the drug causes similar immune changes to those caused by exercise.\n\nParticipants can join one, two, or all three groups. This research will help understand whether exercise can improve immune cell therapies for treating blood cancer and reduce the risk of GvHD, making these treatments safer and more effective.",[30,620,621,622,31,623],"Hematopoetic Stem Cell Transplantation","Donor Lymphocyte Infusion","CAR T-Cell Therapy","Cell Therapy",[625,626,627,628,629,630,631,632,633,634,490,635,636,637],"exercise","cell therapy","beta-blockers","immune function","phosphodiesterase inhibitor","CAR T-cells","NK-cells","cytokine-induced killer cells","cytokine-induced memory-like NK-cells","monoclonal antibodies","lymphoma","donor lymphocyte infusion","gamma-delta T-cells","2026-06-03",{"date":640,"type":41},"2026-06-05",{"date":642,"type":41},"2018-01-24",{"date":644,"type":22},"2031-05-31",{"name":646,"class":81},"University of Arizona",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":17,"minAge":654,"maxAge":655,"enrollmentInfo":656,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":658,"conditions":659,"keywords":673,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":686},"100526212","pharmacokinetic-study-of-venetoclax-tablets-crushed-and-dissolved-into-a-solution-100526212","NCT06131801","Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution","A Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution in Children and Young Adults With Hematologic Malignancies","Inclusion Criteria:\n\n* Age: Patients must be \\\u003C39 years of age at time of study enrollment\n* Diagnosis: Patients may have a diagnosis of any hematologic malignancy\n* Central access: Patients must have an existing venous or arterial access line for PK blood draws\n* Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment\n* Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.\n* Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.\n\nExclusion Criteria:\n\n* Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.\n* Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.","0 Years","38 Years",{"count":657,"type":22},30,"The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.\n\nPrimary Objectives\n\n• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution\n\nSecondary Objectives\n\n* To evaluate the safety of crushed venetoclax tablets administered as an oral solution\n* To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors\n* To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)\n* To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution",[660,30,31,661,17,662,663,664,665,536,66,168,666,667,668,669,670,671,672],"Hematologic Malignancy","Acute Lymphocytic Leukemia","Acute Myelogenous Leukemia","AML","Chronic Myelogenous Leukemia","CML","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Burkitt Lymphoma","T-cell Lymphoma","B Cell Lymphoma","Peripheral T Cell Lymphoma","Cutaneous B-Cell Lymphoma",[674,675,676],"Venetoclax","Pediatric AML","Pediatric Relapsed\u002FRefractory AML","2026-06-02",{"date":679,"type":41},"2026-06-04",{"date":681,"type":41},"2023-11-15",{"date":683,"type":22},"2027-12-01",{"name":685,"class":81},"Children's Hospital Medical Center, Cincinnati",5,{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":691,"acronym":692,"eligibilityCriteria":693,"healthyVolunteers":56,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":694,"targetDuration":4,"studyType":23,"phases":695,"briefSummary":696,"conditions":697,"keywords":699,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":700,"lastUpdatePostDateStruct":701,"startDateStruct":703,"completionDateStruct":705,"leadSponsor":707,"locationsCount":49},"100552147","driving-inclusivity-validity-and-equity-in-research-through-strategic-engagement-diverse-100552147","NCT06469307","Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)","DIVERSE","CAB Participant Inclusion Criteria:\n\n* Age 18 or older\n* English speaking\n* Ability to understand and willingness to provide oral consent\n* DFCI patient who are in remission from a blood cancer \\>1 year will be preferred.\n\nCAB Participant Exclusion Criteria:\n\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers \\\u003C18 years old)\n* Prisoners.\n* Unwilling\u002Funable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1\n* Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed.\n* Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews.\n\nInvestigator Participant Inclusion Criteria:\n\n* Age 18 older\n* English Speaking\n* Site or Principal investigator\n* Not a member of the research team",{"count":584,"type":22},[158],"The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.",[698,30],"Blood Cancer",[698,30],"2026-05-26",{"date":702,"type":41},"2026-05-28",{"date":704,"type":41},"2024-12-09",{"date":706,"type":22},"2027-06-30",{"name":548,"class":81},{"id":709,"slug":710,"hasResults":12,"nctId":711,"briefTitle":712,"officialTitle":712,"acronym":4,"eligibilityCriteria":713,"healthyVolunteers":56,"sex":17,"minAge":88,"maxAge":714,"enrollmentInfo":715,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":717,"conditions":718,"keywords":719,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":725,"lastUpdatePostDateStruct":726,"startDateStruct":728,"completionDateStruct":730,"leadSponsor":731,"locationsCount":49},"100581893","natural-history-study-to-determine-drug-metabolism-phenotype-and-appropriate-germline-source-dna-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplant-100581893","NCT06856226","Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant","* INCLUSION CRITERIA:\n* Age \\>=18 years\n* Participants must be enrolled on a clinical trial at the NIH Clinical Center (CC) under which they will donate or receive an allogeneic HSCT. The participant and their donor must enroll together to provide a complete set of samples for analysis.\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Donors are not allowed to enroll without a recipient\n* Prior allogeneic HSCT\n* History of psychiatric disorder which may compromise compliance with protocol requirements.\n* Pregnant and lactating individuals","120 Years",{"count":716,"type":22},88,"Background:\n\nAfter an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient s circulation and tissues.\n\nPost-HSCT recipients may receive a medication in which the dosing needs to be adjusted based on genetic variation.\n\nWhile genes in donor genome may influence dosing and administration of some agents, the majority of established gene-drug pairs in pharmacogenetics are related to expression of metabolic or transporting enzymes located in recipients tissues, often the liver.\n\nDetermining which genetic variants influence drug disposition in HSCT recipients is complicated by chimerism in samples that are routinely collected for determining genotype. However, chimerism in tissues is poorly studied in this patient population.\n\nObjectives:\n\nTo determine the most reliable host genomic source for pharmacogenetic testing in participants that have received allogeneic HSCT.\n\nEligibility:\n\nPeople ages 18 years and older who are enrolled on a clinical trial at the NIH Clinical Center under which they will donate or receive an allogeneic HSCT.\n\nDesign:\n\nDNA is collected prior to HSCT and for two years after HSCT.\n\nBlood will be collected and skin fibroblast cell lines will be established prior to HSCT to serve as a reference genome.\n\nBlood, buccal cells, skin, and hair will be monitored for the development of mixed chimerism via detection of short tandem repeats. Liver biopsies will be collected from participants undergoing hepatic surgery.\n\nPharmacoscan arrays will be conducted to determine which samples are useful for pharmacogenetic testing in participants who receive allogeneic HSCT.\n\nA probe drug cocktail will be administered pre- and post-HSCT to determine if transplantation alters the metabolic phenotype of liver enzymes.\n\n...",[30,31,660],[720,721,722,723,724],"Allogeneic Transplant","Hematopoietic Cell Transplant","Bone Marrow Transplant","peripheral blood transplant","Chimerism","2026-05-23",{"date":727,"type":41},"2026-05-27",{"date":729,"type":41},"2026-03-04",{"date":520,"type":22},{"name":47,"class":48},{"id":733,"slug":734,"hasResults":12,"nctId":735,"briefTitle":736,"officialTitle":737,"acronym":4,"eligibilityCriteria":738,"healthyVolunteers":56,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":739,"targetDuration":4,"studyType":23,"phases":740,"briefSummary":741,"conditions":742,"keywords":744,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":748,"lastUpdatePostDateStruct":749,"startDateStruct":750,"completionDateStruct":752,"leadSponsor":754,"locationsCount":441},"100597010","a-music-therapy-study-for-blood-cancer-survivors-with-cognitive-difficulties-100597010","NCT07052916","A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties","Pilot Trial of Telehealth Music Therapy for Cognitive Dysfunction in Hematologic Cancer Survivors (PRELUDE)","Inclusion Criteria:\n\n* English-proficient, aged 18 or older\n* Diagnosis of lymphoma, leukemia, or myeloma\n* Stable oncologic disease or no evidence of disease as indicated in the medical chart or by the oncology team\n* Score of \\\u003C54 on the FACT-Cog PCI subscale\n* Minimum life expectancy of one year as per clinician assessment\n* Patient should be able to understand and complete all study assessments on their own.\n* Eligible patient should be able to understand informed consent and provide signed informed consent in English.\n\nExclusion Criteria:\n\n* Less than 3 months since completion of surgery, radiation, induction chemotherapy (for newly diagnosed or relapsed disease), transplantation, or immunotherapy (e.g., CAR T-Cell, bispecific antibodies)\n\n  * If there is a defined treatment period, the patient must be at least 3 months from treatment completion\n  * If the patient is on continuous therapy, patient must have completed at least 6 months of the therapy\n  * Maintenance therapies are allowed\n* Received music therapy (MT) in the past year\n* Current music training, \\>6 months of music training in the past 10 years, or plan to initiate music training during the study\n* No access to an internet-connected device\n* Active suicidal ideation, bipolar, schizophrenia, or substance abuse\n* BOMC score ≥10 (indicative of dementia)\n* Uncorrectable visual, auditory, or motor impairments\n* Initiation or altered dose of sedative, stimulant, or anti-cholinergic medications in the past month or plan to initiate these medications during the study, as these are known to impact cognitive function\n* Initiation of any other interventions for CRCD (e.g., cognitive rehabilitation) in the past month or plan to initiate these interventions during the study, as these are known to impact cognitive function",{"count":91,"type":22},[158],"Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function. Because of this past research, the researchers are doing this study to find out whether telehealth music therapy is a practical treatment for cognitive difficulties in blood cancer survivors. The researchers will also study whether music therapy and music education help improve cognitive function and other common symptoms such as anxiety, depression, and\u002For tiredness.",[698,31,30,743],"Myeloma",[745,746,30,31,462,747],"Blood cancer survivor","myeloma","25-119","2026-05-22",{"date":700,"type":41},{"date":751,"type":41},"2025-06-27",{"date":753,"type":22},"2026-12-27",{"name":462,"class":81},{"id":756,"slug":757,"hasResults":12,"nctId":758,"briefTitle":759,"officialTitle":759,"acronym":4,"eligibilityCriteria":760,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":761,"targetDuration":4,"studyType":23,"phases":763,"briefSummary":764,"conditions":765,"keywords":766,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":767,"lastUpdatePostDateStruct":768,"startDateStruct":770,"completionDateStruct":772,"leadSponsor":773,"locationsCount":49},"100585855","tools-for-reducing-inequity-in-acute-leukemia-trial-beta-testing-100585855","NCT06907797","Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing","Inclusion Criteria:\n\n* Age 18 or older\n* English speaking\n* Ability to understand and willingness to sign written informed consent\n* Clinical suspicion of acute leukemia\n* Admitted to DFCI-affiliated inpatient unit\n\nExclusion Criteria:\n\n* Cognitive impairment rendering the individual unable to participate in beta testing\n\n  * This will be assessed by focused chart review and consultation with the patients' inpatient care team.\n* The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers \\\u003C18 years old), prisoners.\n* Inability to participate in in-person application testing.\n* Patients who participated in alpha-testing through protocol 23-404 (Appendix A)",{"count":762,"type":22},75,[158],"This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.",[455,30],[455,30],"2026-05-18",{"date":769,"type":41},"2026-05-20",{"date":771,"type":41},"2025-04-01",{"date":706,"type":22},{"name":548,"class":81},{"id":775,"slug":776,"hasResults":12,"nctId":777,"briefTitle":778,"officialTitle":779,"acronym":4,"eligibilityCriteria":780,"healthyVolunteers":12,"sex":17,"minAge":125,"maxAge":126,"enrollmentInfo":781,"targetDuration":4,"studyType":23,"phases":783,"briefSummary":784,"conditions":785,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":767,"lastUpdatePostDateStruct":786,"startDateStruct":788,"completionDateStruct":790,"leadSponsor":792,"locationsCount":49},"100488869","phase-2-study-of-pedi-crib-mini-hyper-cvd-with-condensed-rituximab-inotuzumab-ozogamicin-and-blinatumomab-crib-for-relapsed-therapy-for-pediatric-with-b-cell-lineage-acute-lymphocytic-leukemia-100488869","NCT05645718","Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","Inclusion Criteria:\n\n* Pediatric, adolescent, or young adult patients with B-ALL as per NCCN v2.2021 and WHO classification in relapse or primary refractory and, either\u002Fboth of the following: • Unable to receive anthracyclines (see section 3.1.8) or is PEG-asparaginase intolerant.\n\n  * For leukemia: Patients must have ≥ 5% blasts expressing CD19 and CD22 in the bone marrow as assessed by morphology or flow cytometry. However, if an adequate bone marrow sample cannot be obtained, patients may be enrolled if there is unequivocal evidence of leukemia with ≥ 5% blasts in the peripheral blood.\n  * If patient does not have CD20, they can still be enrolled but will not receive rituximab.\n* Performance status: Lansky ≥ 50 for patients who are ≤ 16 years old and Karnofsky ≥ 50% for patients who are \\> 16 years old.\n* Patients with asymptomatic CNS leukemia are eligible (see also Exclusion Criterion 3.2.2.)\n* Age \\> = 1 years of age and less than 25 years of age.\n* The following baseline laboratory data:\n\n  * Total serum bilirubin ≤1.5x upper limit of normal (ULN). Patients with known Gilbert's syndrome may have a total bilirubin up to ≤3 x ULN.\n  * Adequate renal function per age51 unless related to the disease. Estimated glomerular filtration rate ≥ 60 mL\u002Fmin\u002F1.73 m2 based on local institutional practice for age-appropriate determination (eg, Schwartz formula for pediatric patients or Cockcroft Gault formula for adults).\n  * Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) ≤3 x ULN; ≤5 x ULN in case of suspected leukemic liver involvement\n* Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use one of the following effective contraception methods during the study and 30 days after the last treatment and 8 months after the last dose of inotuzumab and 12 months after the last dose of rituximab. Effective methods of birth control include:\n\n  * Birth control pills, shots, implants (placed under the skin by a health care provider) or patches (placed on the skin)\n  * Intrauterine devices (IUDs)\n  * Condom or occlusive cap (diaphragm or cervical\u002Fvault caps) used with Spermicide\n  * Abstinence\n* Males need to inform the doctor right away if the partner becomes pregnant or suspects pregnancy. While in this study and for 30 days after the last treatment the patient should not donate sperm for the purposes of reproduction. He will need to use a condom while in this study and for 30 days after the last treatment and 5 months after the last dose of inotuzumab.\n* Patients with cardiac disease, include but not limited to: (Left ventricular ejection fraction (EF) \\\u003C 50% (as determined by the Biplane Simpson method) (but not per exclusion criteria 3.2.3.1), or who have received \\>450mg\u002Fm2 of doxorubicin and cannot receive anthracyclines.\n\nExclusion Criteria:\n\n* Past or current history of a secondary or other primary tumor or a chronic myeloid leukemia (CML) blast crisis with exception of:\n\n  * Curatively treated non-melanomatous skin cancer\n  * Other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 2 years\n* Presence of clinically significant uncontrolled CNS pathology such as epilepsy, childhood seizure, paresis, aphasia, stroke, severe brain injuries, organic brain syndrome, or psychosis. Presence of the following are allowed: headaches, vomiting, nerve palsy\n* Medical history of cardiovascular disease such as:\n\n  ° Clinically significant cardiac disease including congestive heart failure (NYHA class III or IV) or arrhythmia or conduction abnormality requiring medication\n* Patients with uncontrolled, active infections (viral, bacterial, or fungal). Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines are acceptable.\n* Known active hepatitis B or C infection or known seropositivity for HIV.\n* Patients with liver cirrhosis or other serious active liver disease or with suspected active alcohol abuse.\n* Active acute\u002Fchronic Graft-versus-Host Disease (GvHD) requiring systemic treatment; or receiving immunosuppression for GvHD prophylaxis within 2 weeks from the start of study therapy.\n* If patient has not recovered (as deemed by the investigator) from previous chemotherapy, surgery, radiation before the start of study drugs.\n\n  ° To reduce the circulating blast count or palliation, the following are allowed prior to starting: Single dose intravenous cytarabine, steroids or hydroxyurea. No washout necessary for these agents.\n* Females who are pregnant or lactating.\n* Male or female subjects of childbearing potential, unwilling to use an approved, effective means of contraception in accordance with institution's standards.\n* Other severe, uncontrolled acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated Protocol 2022-0312 V3 Dated 11\u002F9\u002F2023 Property of Leukemia at MD Anderson 17 with study participation or investigational product administration or may interfere with the interpretation of study results and\u002For would make the patient inappropriate for enrollment into this study.\n* Patients with Trisomy 21, or bone marrow failure syndromes are not eligible.\n* Prior history of allergic reaction to any of the agents.\n* Patients who are unable or unwilling to comply with all study requirements for clinical visits, examinations, tests, and procedures.\n* Patients may be excluded if they are currently enrolled in another ongoing clinical trial with investigational products",{"count":782,"type":22},27,[25],"To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control the disease.",[30],{"date":787,"type":41},"2026-05-19",{"date":789,"type":41},"2023-07-14",{"date":791,"type":22},"2029-12-31",{"name":793,"class":81},"M.D. Anderson Cancer Center",{"id":795,"slug":796,"hasResults":12,"nctId":797,"briefTitle":798,"officialTitle":798,"acronym":4,"eligibilityCriteria":799,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":800,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":802,"conditions":803,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":767,"lastUpdatePostDateStruct":808,"startDateStruct":809,"completionDateStruct":811,"leadSponsor":813,"locationsCount":49},"100440111","neurocognitive-outcomes-after-whole-brain-radiation-therapy-for-hematologic-malignancies-100440111","NCT05011045","Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies","Inclusion Criteria:\n\n* Age 18 years or older\n* Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \\[PCNSL\\], secondary central nervous system lymphoma \\[SCNSL\\], leukemia, myeloma)\n* Proficient and capable of completing tests in English\n* Patients with claustrophobia are eligible if the claustrophobia is managed with medication\n* Patients with cognitively-impairment are eligible if the impairment is managed with medication\n* Patients who are pregnant",{"count":801,"type":22},100,"This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.",[804,805,30,31,806,807],"Central Nervous System Lymphoma","Hematopoietic and Lymphoid Cell Neoplasm","Plasma Cell Myeloma","Secondary Central Nervous System Lymphoma",{"date":769,"type":41},{"date":810,"type":41},"2020-01-09",{"date":812,"type":22},"2026-10-31",{"name":793,"class":81},{"id":815,"slug":816,"hasResults":12,"nctId":817,"briefTitle":818,"officialTitle":818,"acronym":819,"eligibilityCriteria":820,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":821,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":823,"conditions":824,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":826,"lastUpdatePostDateStruct":827,"startDateStruct":828,"completionDateStruct":830,"leadSponsor":832,"locationsCount":834},"100632376","cohort-of-patients-with-chronic-myelomonocytic-leukemia-100632376","NCT07512882","Cohort of Patients With Chronic Myelomonocytic Leukemia","MYELOMONO-3","Inclusion Criteria:\n\n* Adults aged 18 years and over\n* Blood monocytosis ≥ 0.5 × 10⁹\u002FL and ≥ 10% of total white blood cells or\n* Confirmed diagnosis of chronic myelomonocytic leukemia\n* Regardless of stage (chronic or transformed), and whether or not currently being treated\n* Signed informed consent\n\nExclusion Criteria:\n\n* Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV)\n* Refusal informed consent",{"count":822,"type":22},5000,"A prospective, non-interventional study involving the collection of biological samples with associated anonymised data.\n\nBiological samples will be collected at the time of diagnosis and\u002For as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.",[30,825],"Myelomonocytic Leukemia, Chronic","2026-05-15",{"date":787,"type":41},{"date":829,"type":41},"2026-05-05",{"date":831,"type":22},"2040-03",{"name":833,"class":81},"Gustave Roussy, Cancer Campus, Grand Paris",24,{"id":836,"slug":837,"hasResults":12,"nctId":838,"briefTitle":839,"officialTitle":840,"acronym":4,"eligibilityCriteria":841,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":192,"enrollmentInfo":842,"targetDuration":4,"studyType":23,"phases":843,"briefSummary":844,"conditions":845,"keywords":870,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":826,"lastUpdatePostDateStruct":874,"startDateStruct":875,"completionDateStruct":877,"leadSponsor":879,"locationsCount":49},"100310864","phase-1-ha-1-t-tcr-t-cell-immunotherapy-for-the-treatment-of-patients-with-relapsed-or-refractory-acute-leukemia-after-donor-stem-cell-transplant-100310864","NCT03326921","HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant","Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)","Inclusion Criteria:\n\n* Subject age 0-80 years at the time of enrollment.\n* Subject must express HLA-A\\*0201\n* Subject must have the HA-1(H) genotype (RS\\_1801284: A\u002FG, A\u002FA)\n* Subject must have an adult donor for HCT who is adequately HLA matched by institutional standards (includes HLA-matched related or unrelated donors, and HLA-mismatched family donors, including haploidentical donors) and is either:\n\n  * HLA-A\\*0201 positive and HA-1(H) negative (RS\\_1801284: G\u002FG) or\n  * HLA-A\\*0201 negative\n* Subjects who are currently undergoing or who previously underwent allogeneic HCT for\n\n  * Acute myeloid leukemia (AML) of any subtype\n  * Acute lymphoid leukemia (ALL) of any subtype\n  * Mixed phenotype\u002Fundifferentiated\u002Fany other type of acute leukemia, including blastic plasmacytoid dendritic cell neoplasm\n  * Chronic myeloid leukemia with a history of blast crisis and:\n\n    * With relapse or refractory disease (\\>= 5% marrow blasts, or circulating blasts) at any time after HCT\n    * With persistent rising minimal residual disease (defined as detectable disease by morphology, flow cytometry, molecular or cytogenetic testing but \\\u003C 5% marrow blasts by morphology, no circulating blasts on \\>= 2 of two consecutive tests), refractory or ineligible for treatment with tyrosine kinase inhibitors at any time after HCT\n  * Myelodysplastic syndrome (MDS) of any subtype\n  * Chronic myelomonocytic leukemia (CMML)\n  * Juvenile myelomonocytic leukemia (JMML)\n* Subjects must be able to understand and be willing to give informed consent; decision-impaired adults may consent with their legally authorized representative; parent or legal representative will be asked to consent for subjects younger than 18 years old\n* Subjects must agree to participate in long-term follow-up for up to 15 years if they are enrolled in the study and receive T cell infusion\n* Subjects who have relapsed or have MRD after HCT may receive other agents for treatment of disease and remain eligible for the protocol\n* A specific performance status score is not required for enrolling on the protocol; a delay in infusion of the HA-1 TCR T cells may be required for subjects with low performance status\n\nDONOR SELECTION INCLUSION\n\n* Donor age \\>= 18 years\n* Donors must be able to give informed consent\n\nExclusion Criteria:\n\n* Medical or psychological conditions that would make the subject unsuitable candidate for cell therapy at the discretion of the principal investigator (PI)\n* Fertile subjects unwilling to use contraception during and for 12 months after treatment\n* Subjects with a life expectancy of \\\u003C 3 months of enrollment from coexisting disease other than leukemia\n* Subjects who have ongoing grade IV acute GVHD or severe chronic GVHD following most recent transplant. Exception: the principal investigator (PI) may make an exception on a case-by-case basis to include such a subject if there is doubt surrounding the GVHD diagnosis and\u002For sustained significant improvement in GVHD severity\n* The presence of organ toxicities will not necessarily exclude subjects from enrolling on the protocol at the discretion of the PI; however, a delay in the infusion of HA-1 TCR T cells may be required\n\nDONOR SELECTION EXCLUSION\n\n* Donors who are human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection\n* Unrelated donor residing outside of the United States of America (USA) unless the donor screening, testing and leukapheresis occur at an National Marrow Donor Program (NMDP)-affiliated and qualified donor center and are facilitated by the NMDP",{"count":834,"type":22},[130],"This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists, has come back (recurrent) or does not respond to treatment (refractory) following donor stem cell transplant. T cell receptor is a special protein on T cells that helps them recognize proteins on other cells including leukemia. HA-1 is a protein that is present on the surface of some peoples' blood cells, including leukemia. HA-1 T cell immunotherapy enables genes to be added to the donor cells to make them recognize HA-1 markers on leukemia cells.",[846,847,848,849,850,851,852,853,854,855,856,857,858,460,859,860,861,862,539,459,133,863,864,865,866,867,868,30,869],"Juvenile Myelomonocytic Leukemia","Recurrent Acute Biphenotypic Leukemia","Recurrent Acute Undifferentiated Leukemia","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Adult Acute Lymphoblastic Leukemia","Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Myelodysplastic Syndrome","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Myelodysplastic Syndrome","Acute Undifferentiated Leukemia","Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive","Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Acute Biphenotypic Leukemia","Chronic Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Minimal Residual Disease","Recurrent Chronic Myelomonocytic Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Chronic Myeloid Leukemia, BCR-ABL1 Positive",[871,872,873,30],"HA-1","TCR","Immunotherapy",{"date":767,"type":41},{"date":876,"type":41},"2018-02-23",{"date":878,"type":22},"2028-07-16",{"name":880,"class":81},"Fred Hutchinson Cancer Center",{"id":882,"slug":883,"hasResults":12,"nctId":884,"briefTitle":885,"officialTitle":886,"acronym":4,"eligibilityCriteria":887,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":888,"enrollmentInfo":889,"targetDuration":4,"studyType":23,"phases":891,"briefSummary":892,"conditions":893,"keywords":895,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":898,"lastUpdatePostDateStruct":899,"startDateStruct":901,"completionDateStruct":903,"leadSponsor":905,"locationsCount":49},"100636491","phase-2-cord-blood-transplantation-in-children-and-young-adults-with-blood-cancer-100636491","NCT07566377","Cord Blood Transplantation in Children and Young Adults With Blood Cancer","Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies","Inclusion Criteria:\n\nA patient cannot be considered eligible for this study unless ALL of the following conditions are met.\n\n° Disease type\n\nCohort 1, High Risk Disease: Patients with age ≤ 26 years at the time of informed consent with no available and suitably matched related or unrelated donor within 4 weeks, with one of the following diagnoses:\n\nI. Acute myelogenous leukemia (AML):\n\n* Complete first remission (CR1) with blast count \\\u003C 5% by bone marrow morphology at high risk for relapse such as any of the following:\n\n  * Known prior diagnosis of myelodysplasia (MDS)\n  * High risk cytogenetics (e.g., those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) and\u002For high-risk molecular abnormalities (e.g., TP53)\n  * Requirement for 2 or more inductions to achieve CR1\n  * Therapy-related AML (t-AML) or therapy-related myeloid neoplasm (t-MN) (including after therapy for other malignancy, and\u002For gene therapy or cell therapy)\n  * Presence of Minimal\u002FMeasurable Residual Disease (MRD+) by cytogenetics, flow cytometry or molecular methods (at End of Induction or End of Consolidation)\n  * Other high-risk features not defined above.\n* Complete second remission (CR2) or subsequent remission, with blast count \\\u003C 5% by bone marrow morphology\n* Presence of MRD by multiparameter flow cytometry at pre-transplant evaluation is acceptable.\n\nII. Acute lymphoblastic leukemia (ALL):\n\n* Complete first remission (CR1) with MRD negative status by multicolor flow cytometry, at high risk for relapse such as any of the following:\n\n  * Presence of any high risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other, KMT2A (11q23) or other high risk molecular abnormality\n  * Failure to achieve complete remission (CR) after four weeks of induction therapy (transplant to follow antibody therapy and\u002For CAR T cells)\n  * Persistence or recurrence of MRD on therapy (Transplant to follow antibody therapy and\u002For CAR T cells)\n  * T-ALL in CR even with presence of MRD\n  * Other high-risk features not defined above\n* Complete second remission (CR2) or subsequent remission with MRD negative status by multiparameter flow cytometry.\n\n  * Relapse in less than 36 months from CR1\n  * Relapse for T-ALL\n* Patients after antibody therapy (e.g., blinatumomab, inotuzumab, other) and\u002For CAR-T cell therapy that resulted in MRD negative status by multiparameter flow cytometry.\n\nIII. Other acute leukemias:\n\n* Leukemias of ambiguous lineage or of other types with \\\u003C 5% blasts by bone marrow morphology.\n* Patients with persistent\u002Frelapsed disease with cytogenetic, flow cytometric or molecular aberrations in \\\u003C 5% of cells.\n* Chronic myelogenous leukemia: Patients with history of blast crisis or accelerated phase.\n* Any leukemia that developed after gene therapy or cell therapy\n\nIV. Myelodysplastic Syndrome (MDS):\n\n* Any IPSS risk category with life-threatening cytopenia(s).\n* Any IPSS risk category with high risk cytogenetic\u002Fmolecular findings (5, 7, 8, complex karyotype, or TP53)\n\nV. Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high risk of relapse or progression if not in remission:\n\n* Patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell NHL) in CR.\n* Patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease\u002F CR\u002F PR with no single lesion equal to or more than 5 cm.\n* Patients with HL without progression of disease (POD) after salvage chemotherapy with no single lesion ≥5 cm.\n\nCohort 2: Very High-Risk disease:\n\n1. Patients in CR (bone marrow blasts \\\u003C5% by morphology) who had prior allogeneic transplant and disease recurrence. The second transplant will take place at least 4 months after the first.\n\n   * Acute myelogenous leukemia (AML) or Myelodysplastic Syndrome (MDS): Relapse after previous transplant, in CR after induction therapy. MRD positive status by multi-parameter flow cytometry is accepted.\n   * Acute lymphoblastic leukemia (ALL): Relapse after previous transplant, in CR after induction therapy and\u002For antibody therapy\u002FCAR T cells. MRD positive status after targeted therapy, as evaluated by multi-parameter flow cytometry is accepted.\n   * Other: patients with leukemia or lymphoma, who, in the opinion of their physician, are not likely to have reduction in disease burden with further chemotherapy.\n2. Patients with relapsed\u002Frefractory disease at either first or second allogeneic transplant, with up to 30% bone marrow blasts by multiparameter flow cytometry or morphology. ° Relapse after previous transplant with \\\u003C 30% blasts by bone marrow morphology, or with cytogenetic, flow cytometric, or molecular abnormalities in \\\u003C 30% of bone marrow cells, after induction therapy.\n\n   ° Primary refractory or relapsed AML with \\\u003C 30% blasts by bone marrow morphology or with cytogenetic, flow cytometric, or molecular abnormalities in \\\u003C 30% of bone marrow cells.\n\n   ° Age 0-26 years at the time of informed consent\n\n   ° Performance: Karnofsky (≥16 years) or Lansky score (\\\u003C16 years) of ≥70% (see Appendix A).\n\n   ° Not Pregnant and Not Nursing\n\n   ° Required Organ Function\n   * Bilirubin ≤ 1.5 mg\u002FdL (unless benign congenital hyperbilirubinemia).\n   * ALT ≤ 3 x upper limit of normal.\n   * Pulmonary function (FVC, FEV1 and DLCO corrected for hemoglobin) ≥ 50% predicted.\n\n     * In young children unable to perform pulmonary function testing: pulse oximetry \\>92% in room air, and a normal CT of the chest (if CT is not normal, the child needs to be evaluated and cleared by pediatric pulmonary physician).\n   * Left ventricular ejection fraction \\> 50%.\n   * Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) ≤ 7.\n   * Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of enrolment and must be willing to use an effective contraceptive method while enrolled in the study.\n   * Renal: Serum creatinine (SCr) ≤ 1.5 x normal for age. If SCr is outside the normal range, then CrCl \\> 50 mL\u002Fmin (calculated or estimated) or estimated GFR (mL\u002Fmin\u002F1.73m2) \\>30% of predicted normal for age.\n\n   Normal GFR by Age : Mean GFR +- SD (mL\u002Fmin\u002F1.73m\\^2) 1 week : 40.6 + \u002F - 14.8 2-8 weeks : 65.8 + \u002F - 24.8 \\>8 weeks : 95.7 + \u002F - 21.7 2-12 years : 133.0 + \u002F - 27.0 13-21 years (males) : 140.0 + \u002F - 30.0 13-21 years (females) : 126.0 + \u002F - 22.0\n\n   GFR, glomerular filtration rate; SD, standard deviation; Greater than 2 years old: Normal GFR is 100 mL\u002F min; Infants: GFR must be corrected for body surface area.\n\n   Exclusion Criteria:\n\n   Exclusion criteria for both cohorts:\n\n   ° Inadequate performance status\u002F organ function.\n\n   ° Active CNS leukemic involvement.\n   * Chloroma \\>2 cm.\n   * Active and uncontrolled infection (bacterial\u002Ffungal\u002Fviral) at time of transplant.\n   * HIV infection.\n   * Seropositivity for HTLV-1.\n   * Pregnancy or breast feeding.\n   * Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests.\n   * Any abnormal condition or lab result that is considered by the PI capable or altering patient's condition or study outcome.\n\n   Cohort 2 Very High-Risk Disease (additional to above):\n\n   ° Allogeneic HCT in the preceding 4 months.\n\n   Note (1): Prior checkpoint inhibitors\u002Fblockade in the last 12 months: eligibility to be discussed with study PI.\n\n   Note (2): For patients with known HBV and\u002For HCV infection :\n   * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n   * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.","26 Years",{"count":890,"type":22},71,[25],"The purpose of this study is to find out whether Cord Blood Transplantation\u002FCBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.",[662,133,97,165,168,30,31,894],"Graft-versus-host Disease",[896,894,31,30,168,165,97,133,662,462,897],"Cord blood transplants","26-168","2026-05-11",{"date":900,"type":41},"2026-05-14",{"date":902,"type":41},"2026-04-28",{"date":904,"type":22},"2030-04-28",{"name":462,"class":81}]